Skip to content
Laboratory assesment of direct and indirect thrombin inhibitors
6th ECAT International Symposium 2008
Speaker
Titel
Abstract
Presentation
M. Spannagl
Laboratory assesment of direct and indirect thrombin inhibitors
Related items
Analytical Information :
2
Influence of DOAC Stop on coagulation assays in samples from patients on rivaroxaban or apixaban
Interference of rivaroxaban in one-stage and chromogenic factor VIII:C assays
Cases :
1
Acquired Hemophilia A, case study
ECAT Documents :
20
Low Molecular Weight Heparin (LMWH)
Heparin-Unfractionated
International external quality assessment for measurements of direct oral anticoagulants: results and recommendations.
Quality performance for indirect Xa inhibitor monitoring in patients using international external quality data
New developments in laboratory tests
Desired tests for monitoring new anticoagulation drugs
An update on new anticoagulation drugs
Measurement of new oral anticoagulans
ECAT survey results on direct oral anticoagulant testing
Monitoring new oral anticoagulants-Practical approach
The future of anticoagulation
Thrombosis webinar 2021, Antiphospholipid Antibody, Anticoagulation bridging
Medical device thrombosis
Developmental haemostasis: consequences for clinical practice
Results of ECAT EQA programme on DOACS
Interference of DOACS in coagulation tests
Guidance for laboratory testing of DOACS
Interferences in Lupus testing
Sinus thrombosis, past, present and future
Impact of COVID-19 pandemic on the quality of test output in haemostasis laboratories
Guidelines :
2
ICSH Recommendations for Laboratory Measurement of Direct Oral Anticoagulants
Update Recommendations for Laboratory Measurement of Direct Oral Anticoagulants, ICSH recommendations
Quality Issues :
2
Results of the surveys for heparin monitoring
External quality assessment for Rivaroxaban and Dabigatran
Questions or suggestions?
Clotpedia Support Form
Submit
Success